Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for tlr agonists in inducing cellular and humoral responses

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Milicic, Anita ^a   Kaur, Randip ^b   Reyes Sandoval, Arturo ^a   Tang, Choon Kit ^a   Honeycutt, Jared ^a   Perrie, Yvonne ^b   Hill, Adrian V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLDIOCTADECYLAMMONIUM; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; LIPOSOME; OVALBUMIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TREHALOSE 6,6 DIBEHENATE; UNCLASSIFIED DRUG; ANTIBODY; CATION; GLYCOLIPID; QUATERNARY AMMONIUM DERIVATIVE; TOLL LIKE RECEPTOR; TREHALOSE 6,6' DIBEHENATE; TREHALOSE 6,6'-DIBEHENATE; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; LIPID MEMBRANE; MOUSE; NONHUMAN; PARTICLE SIZE; SIGNAL TRANSDUCTION; SPLEEN CELL; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; IMMUNOLOGY;

ANIMALIA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; CATIONS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GLYCOLIPIDS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OVALBUMIN; QUATERNARY AMMONIUM COMPOUNDS; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS; VACCINES;

EID: 84859073172     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034255     Document Type: Article

References (46)

1. Gregoriadis G, Ryman BE, (1971) Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases. Biochem J 124: 58.
2. Jain AK, Chalasani KB, Khar RK, Ahmed FJ, Diwan PV, (2007) Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery. J Drug Target 15: 417-427.
3. Rahman YE, Rosenthal MW, Cerny EA, Moretti ES, (1974) Preparation and prolonged tissue retention of liposome-encapsulated chelating agents. J Lab Clin Med 83: 640-647.
4. Gregoriadis G, Wills EJ, Swain CP, Tavill AS, (1974) Drug-carrier potential of liposomes in cancer chemotherapy. Lancet 1: 1313-1316.
5. Gregoriadis G, (1994) The immunological adjuvant and vaccine carrier properties of liposomes. J Drug Target 2: 351-356.
6. Alving CR, (1992) Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Biochim Biophys Acta 1113: 307-322.
7. Gregoriadis G, (1990) Immunological adjuvants: a role for liposomes. Immunol Today 11: 89-97.
8. Davis D, Gregoriadis G, (1987) Liposomes as adjuvants with immunopurified tetanus toxoid: influence of liposomal characteristics. Immunology 61: 229-234.
9. Kahl LP, Scott CA, Lelchuk R, Gregoriadis G, Liew FY, (1989) Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization. J Immunol 142: 4441-4449.
10. Brunel F, Darbouret A, Ronco J, (1999) Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine. Vaccine 17: 2192-2203.
11. Gluck R, (1995) Liposomal presentation of antigens for human vaccines. In: Powell MJ, editors. Vaccine design: The Subunit and Adjuvant Approach New York Plenum Press pp. 347-361.
12. Gregoriadis G, McCormack B, Obrenovic M, Perrie Y, Saffie R, (2000) Vaccine adjuvants: Preparation Methods and Research Protocols Totowa(New Jersey) Humana Press pp. 137-150.
13. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, et al. (2005) Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 1718: 22-31.
14. Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P, (2004) Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 72: 1608-1617.
15. Christensen D, Korsholm KS, Andersen P, Agger EM, (2011) Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 10: 513-521.
16. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, et al. (2008) Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 3: e3116.
17. Seltzer SE, Gregoriadis G, Dick R, (1988) Evaluation of the dehydration-rehydration method for production of contrast-carrying liposomes. Invest Radiol 23: 131-138.
18. Taneichi M, Tanaka Y, Kasai M, Mori M, Nishida M, et al. (2006) Induction of differential T-cell epitope by plain- and liposome-coupled antigen. Bioconjug Chem 17: 899-904.
19. Alving CR, Koulchin V, Glenn GM, Rao M, (1995) Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol Rev 145: 5-31.
20. Shek PN, Sabiston BH, (1982) Immune response mediated by liposome-associated protein antigens. II. Comparison of the effectiveness of vesicle-entrapped and surface-associated antigen in immunopotentiation. Immunology 47: 627-632.
21. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P, (2000) ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 68: 791-795.
22. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, et al. (2006) Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 176: 7335-7345.
23. Bal SM, Hortensius S, Ding Z, Jiskoot W, Bouwstra JA, (2011) Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Vaccine 29: 1045-1052.
24. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, et al. (1999) Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 163: 1552-1561.
25. Gursel I, Gursel M, Ishii KJ, Klinman DM, (2001) Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 167: 3324-3328.
26. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S, (1999) Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115-122.
27. Wells JW, Cowled CJ, Farzaneh F, Noble A, (2008) Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity. J Immunol 181: 3422-3431.
28. Bagchi A, Herrup EA, Warren HS, Trigilio J, Shin HS, et al. (2007) MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol 178: 1164-1171.
29. Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, et al. (2003) Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 171: 3154-3162.
30. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, et al. (2002) Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 32: 1958-1968.
31. Hacker H, Mischak H, Miethke T, Liptay S, Schmid R, et al. (1998) CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 17: 6230-6240.
32. Edwards AD, Manickasingham SP, Sporri R, Diebold SS, Schulz O, et al. (2002) Microbial recognition via Toll-like receptor-dependent and-independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering. J Immunol 169: 3652-3660.
33. de Cassan SC, Forbes EK, Douglas AD, Milicic A, Singh B, et al. (2011) The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J Immunol 187: 2602-2616.
34. Blander JM, Medzhitov R, (2006) On regulation of phagosome maturation and antigen presentation. Nat Immunol 7: 1029-1035.
35. Henriksen-Lacey M, Devitt A, Perrie Y, (2011) The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J Control Release 154: 131-137.
36. Kaur R, Bramwell VW, Kirby DJ, Perrie Y, (2011) Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses. J Control Release.
37. Tanaka Y, Kasai M, Taneichi M, Naito S, Kato H, et al. (2004) Liposomes with differential lipid components exert differential adjuvanticity in antigen-liposome conjugates via differential recognition by macrophages. Bioconjug Chem 15: 35-40.
38. Nair S, Zhou F, Reddy R, Huang L, Rouse BT, (1992) Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med 175: 609-612.
39. Meier O, Boucke K, Hammer SV, Keller S, Stidwill RP, et al. (2002) Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J Cell Biol 158: 1119-1131.
40. Amstutz B, Gastaldelli M, Kalin S, Imelli N, Boucke K, et al. (2008) Subversion of CtBP1-controlled macropinocytosis by human adenovirus serotype 3. EMBO J 27: 956-969.
41. Korsholm KS, Agger EM, Foged C, Christensen D, Dietrich J, et al. (2007) The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121: 216-226.
42. Norbury CC, Hewlett LJ, Prescott AR, Shastri N, Watts C, (1995) Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity 3: 783-791.
43. Norbury CC, Chambers BJ, Prescott AR, Ljunggren HG, Watts C, (1997) Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol 27: 280-288.
44. Kirby C, Gregoriadis G, (1984) Dehydration-rehydration vesicles: A simple method for high yield drug entrapment in liposomes. Biotechnology 11: 979-984.
45. Larsen KC, Spencer AJ, Goodman AL, Gilchrist A, Furze J, et al. (2009) Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. Vaccine 27: 5589-5598.
46. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, et al. (2008) Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14: 819-821.